Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026

Jefferies and Johnson Rice maintained Buy on Protagonist Therapeutics, Inc. (PTGX) on March 18, 2026. The PTGX analyst rating updates include a Jefferies price target raise to $121 and a Johnson Rice note that cites Truist modeling for $730,000,000 peak Icotyde royalties. Both firms kept positive stances, leaving the rating intact while adjusting the firm view. Investors should note the mixed market reaction and the broader coverage context behind these decisions.

PTGX analyst rating: what changed on March 18, 2026

Jefferies on March 18, 2026 maintained a Buy rating and raised its price target to $121. source

Johnson Rice on March 18, 2026 also maintained a Buy rating and relayed Truist’s modeling that projects $730,000,000 peak royalty revenue for Icotyde. source

PTGX price target and revenue assumptions

Jefferies set a new price target of $121, signaling higher upside versus prior targets. This concrete price target gives investors a clearer valuation anchor for PTGX.

Johnson Rice highlighted a Truist model estimating $730,000,000 peak Icotyde royalties, supporting a sustained revenue pathway even without a specific price target from Johnson Rice.

Analyst views and PTGX analyst rating implications

Both firms kept Buy, indicating continued confidence in the Protagonist pipeline and commercial potential. Investors reading the PTGX analyst rating should see stable analyst conviction rather than a directional signal change.

The Jefferies price target raise suggests higher valuation confidence, while the Truist model cited by Johnson Rice stresses long-term royalty upside that underpins that conviction.

Stock reaction and market context

The two notes coincided with modest intraday weakness: Jefferies-linked coverage showed -0.71% (-$0.69) and the Johnson Rice item showed -0.59% (-$0.58) since publication times. This small decline suggests the market priced the updates as confirmation, not a surprise.

With a market cap of $6,195,186,683, PTGX sits in a range where analyst sentiment can move shares, but large moves typically require clinical or commercial catalysts.

Historical analyst coverage for Protagonist Therapeutics and PTGX analyst rating trends

Analyst coverage of Protagonist has been positive overall, with multiple firms tracking pipeline milestones and partner royalty streams. Recent sustained Buy stances continue a pattern of bullish coverage based on Icotyde potential.

Investors should note that analysts have alternated between price target revisions and maintained ratings as clinical and commercial data arrived, so ratings have often reflected evolving models rather than abrupt opinion shifts.

What the PTGX analyst rating means for investors

A maintained Buy from Jefferies and Johnson Rice signals that analysts expect upside from Protagonist’s programs and royalty prospects. Investors should weigh those views against valuation, pipeline risk, and timing of cash flows.

Meyka AI rates PTGX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI is an AI-powered market analysis platform and these grades are not guaranteed and are not financial advice.

Final Thoughts

The March 18, 2026 PTGX analyst rating updates show consistent analyst support for Protagonist Therapeutics, Inc. Both Jefferies and Johnson Rice maintained Buy stances, with Jefferies raising its price target to $121 and Johnson Rice referencing a Truist model that projects $730,000,000 in peak Icotyde royalties. The dual maintenance of Buy underscores continued confidence in the company’s commercial pathway and royalty upside rather than signaling new risk or weakness.

For investors, the immediate takeaway is clarity: analysts are keeping a positive view, and Jefferies’ explicit $121 target creates a valuation benchmark. At the same time, modest intraday share declines after publication show the market viewed these notes as confirmatory. With a market cap of $6,195,186,683 and a Meyka AI rating of B+, PTGX sits in a watchful position where future clinical results and royalty realization will drive larger moves. Use the PTGX analyst rating as one input among valuation, risk tolerance, and time horizon when evaluating Protagonist shares.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.